M. Adachi, M. Barrot, A. E. Autry, D. Theobald, and L. M. Monteggia, Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy, Biol. Psychiatry, vol.63, pp.642-649, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00343691

O. Agid and B. Lerer, Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation, Int. J. Neuropsychopharmacol, vol.6, pp.41-49, 2003.

R. D. Airan, L. A. Meltzer, M. Roy, Y. Gong, H. Chen et al., High-speed imaging reveals neurophysiological links to behavior in an animal model of depression, Science, vol.317, pp.819-823, 2007.

A. C. Akerblad, F. Bengtsson, L. Von-knorring, and L. Ekselius, Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study, Int. Clin. Psychopharmacol, vol.21, pp.117-124, 2006.

B. Alexander, J. Warner-schmidt, T. Eriksson, C. Tamminga, M. Arango-lievano et al., Reversal of depressed behaviors in mice by p11, 2010.

, the nucleus accumbens, vol.2, pp.54-76

G. S. Alexopoulos, C. F. Murphy, F. M. Gunning-dixon, C. E. Glatt, V. Latoussakis et al., Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression, J. Affect. Disord, vol.119, pp.132-141, 2009.

G. S. Alexopoulos, C. F. Murphy, F. M. Gunning-dixon, V. Latoussakis, D. Kanellopoulos et al., Microstructural white matter abnormalities and remission of geriatric depression, Am. J. Psychiatry, vol.165, pp.238-244, 2008.

L. L. Altshuler, M. Bauer, M. A. Frye, M. J. Gitlin, J. Mintz et al., Does thyroid supplementation accelerate tricyclic antidepressant response. A review and meta-analysis of the literature, Am. J. Psychiatry, vol.158, pp.1617-1622, 2001.

A. Anand, Y. Li, Y. Wang, J. Wu, S. Gao et al., Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study, Neuropsychopharmacology, vol.30, pp.1334-1344, 2005.

L. Andrade, J. J. Caraveo-anduaga, P. Berglund, R. V. Bijl, R. De-graaf et al., The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys, Int. J. Methods Psychiatr. Res, vol.12, pp.3-21, 2003.

R. Aronson, H. Offman, R. Joffe, and C. Naylor, Triiodothyronine augmentation in treatment of refractory depression, Arch. Gen. Psychiatry, vol.53, pp.842-848, 1996.

A. Bacq, L. Balasse, G. Biala, B. Guiard, A. M. Gardier et al., Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response, Mol. Psychiatry, vol.17, pp.926-939, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00661249

T. Baghai, C. Schule, P. Zill, T. Deiml, D. Eser et al., The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men, Neurosci. Lett, vol.363, pp.38-42, 2004.

F. R. Bambico and C. Belzung, Novel Insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis, Neurogenesis and Neural Plasticity, vol.15, 2013.

. Heidelberg, , pp.243-291

M. Bares, M. Brunovsky, M. Kopecek, T. Novak, P. Stopkova et al., Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder, Eur. Psychiatry, vol.23, pp.350-355, 2008.

K. G. Bath, D. Q. Jing, I. Dincheva, C. C. Neeb, S. S. Pattwell et al., BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity, Neuropsychopharmacology, vol.37, pp.1297-1304, 2012.

M. Bauer, T. Bschor, A. Pfennig, P. C. Whybrow, J. Angst et al., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care, World J. Biol. Psychiatry, vol.8, pp.67-104, 2007.

M. Bauer, D. H. Silverman, F. Schlagenhauf, E. D. London, C. L. Geist et al., Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy, J. Clin. Endocrinol. Metab, vol.94, pp.2922-2929, 2009.

B. T. Baune, C. Hohoff, K. Berger, A. Neumann, S. Mortensen et al., Association of the COMT val158met variant with antidepressant treatment response in major depression, Neuropsychopharmacology, vol.33, pp.924-932, 2008.

C. Belzung, . Billette-de, and E. Villemeur, The design of new antidepressants: can formal models help. A first attempt using a model of the hippocampal control over the HPA axis based on a review from the literature, Behav. Pharmacol, vol.21, pp.677-689, 2010.

E. E. Benarroch, Blood-brain barrier: recent developments and clinical correlations, Neurology, vol.78, pp.1268-1276, 2012.

F. Benedetti, C. Colombo, A. Pirovano, E. Marino, and E. Smeraldi, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting, Psychopharmacology, vol.203, pp.155-160, 2009.

M. T. Berlim and G. Turecki, What is the meaning of treatment resistant/refractory major depression (TRD). A systematic review of current randomized trials, Eur. Neuropsychopharmacol, vol.17, pp.696-707, 2007.

E. Berrocoso and J. A. Mico, Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression, Int. J. Neuropsychopharmacol, vol.12, pp.1033-1044, 2009.

J. M. Bessa, D. Ferreira, I. Melo, F. Marques, J. J. Cerqueira et al., The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling, Mol. Psychiatry, vol.14, pp.764-773, 2009.

B. H. Bewernick, S. Kayser, V. Sturm, and T. E. Schlaepfer, Longterm effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy, Neuropsychopharmacology, vol.37, 1975.

E. B. Binder, H. E. Künzel, T. Nickel, N. Kern, A. Pfennig et al., HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients, Psychoneuroendocrinology, vol.34, pp.99-109, 2009.

E. B. Binder, D. Salyakina, P. Lichtner, G. M. Wochnik, M. Ising et al., Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment, Nat. Genet, vol.36, pp.1319-1325, 2004.

C. Bock, J. D. Bukh, M. Vinberg, U. Gether, and L. V. Kessing, Do stressful life events predict medical treatment outcome in first episode of depression, Soc. Psychiatry Psychiatr. Epidemiol, vol.44, pp.752-760, 2009.

D. E. Bohning, M. P. Lomarev, S. Denslow, Z. Nahas, A. Shastri et al., Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI, Invest. Radiol, vol.36, pp.470-479, 2001.

M. Boldrini, R. Hen, M. D. Underwood, G. B. Rosoklija, A. J. Dwork et al., Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression, Biol. Psychiatry, vol.72, pp.562-571, 2012.

M. Boldrini, A. N. Santiago, R. Hen, A. J. Dwork, G. B. Rosoklija et al., Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression, Neuropsychopharmacology, vol.38, pp.1068-1077, 2013.

M. Boldrini, M. D. Underwood, R. Hen, G. B. Rosoklija, A. J. Dwork et al., Antidepressants increase neural progenitor cells in the human hippocampus, Neuropsychopharmacology, vol.34, pp.2376-2389, 2009.

C. O. Bondi, J. D. Jett, and D. A. Morilak, Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated byalpha1-adrenergic receptors in medial prefrontal cortex, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.34, pp.913-923, 2010.

G. Bondolfi, C. Chautems, B. Rochat, G. Bertschy, and P. Baumann, Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation, Psychopharmacology (Berl.), vol.128, pp.421-425, 1996.

B. Bondy, T. C. Baghai, P. Zill, C. Schule, D. Eser et al., Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.29, pp.1094-1099, 2005.

A. Bortolozzi, A. Castañé, J. Semakova, N. Santana, G. Alvarado et al., Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects, Mol. Psychiatry, vol.17, pp.612-623, 2012.

J. M. Broadway, P. E. Holtzheimer, M. R. Hilimire, N. A. Parks, J. E. Devylder et al., Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatmentresistant depression: a pilot study, Neuropsychopharmacology, vol.37, pp.1764-1772, 2012.

D. M. Brochet, P. Martin, P. Soubrié, and P. Simon, Triiodothyronine potentiation of antidepressant-induced reversal of learned helplessness in rats, Psychiatry Res, vol.21, pp.267-275, 1987.

K. Brosen, Some aspects of genetic polymorphism in the biotransformation of antidepressants, Therapie, vol.59, pp.5-12, 2004.

J. P. Brouwer, B. C. Appelhof, E. F. Van-rossum, J. W. Koper, E. Fliers et al., Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression, Psychoneuroendocrinology, vol.31, pp.1154-1163, 2006.

M. R. Bruchas, A. G. Schindler, H. Shankar, D. I. Messinger, M. Miyatake et al., Selective p38? MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction, Neuron, vol.71, pp.498-511, 2011.

G. E. Bruder, J. P. Sedoruk, J. W. Stewart, P. J. Mcgrath, F. M. Quitkin et al., Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre-and post-treatment findings, Biol. Psychiatry, vol.63, pp.1171-1177, 2008.

G. E. Bruder, J. W. Stewart, P. J. Mcgrath, D. Deliyannides, and F. M. Quitkin, Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men, Neuropsychopharmacology, vol.29, pp.1752-1761, 2004.

G. E. Bruder, J. W. Stewart, C. E. Tenke, P. J. Mcgrath, P. Leite et al., Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant, Biol. Psychiatry, vol.48, pp.416-425, 2001.

N. S. Burghardt, E. H. Park, R. Hen, and A. A. Fenton, Adult-born hippocampal neurons promote cognitive flexibility in mice, Hippocampus, vol.22, pp.1795-1808, 2012.

L. L. Carpenter, L. Bayat, F. Moreno, M. A. Kling, L. H. Price et al., Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy, Psychiatry Res, vol.157, pp.123-129, 2008.

L. L. Carpenter, A. R. Tyrka, J. K. Lee, A. P. Tracy, C. W. Wilkinson et al., A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults, Psychopharmacology (Berl.), vol.218, pp.371-379, 2011.

A. Cattaneo, M. Gennarelli, R. Uher, G. Breen, A. Farmer et al., Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets, Neuropsychopharmacology, vol.38, pp.377-385, 2013.

A. T. Cheng, T. H. Chen, C. C. Chen, and R. Jenkins, Psychosocial and psychiatric risk factors for suicide. Case-control psychological autopsy study, Br. J. Psychiatry, vol.177, pp.360-365, 2000.

Z. Y. Chen, D. Jing, K. G. Bath, A. Ieraci, T. Khan et al., Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior, Science, vol.314, pp.140-143, 2006.

J. Choi, B. Jeong, M. L. Rohan, A. M. Polcari, and M. H. Teicher, Preliminary evidence for white matter tract abnormalities in young adults exposed to parental verbal abuse, Biol. Psychiatry, vol.65, pp.227-234, 2009.

C. D. Clelland, M. Choi, C. Romberg, G. D. Clemenson, A. Fragniere et al., A functional role for adult hippocampal neurogenesis in spatial pattern separation, Science, vol.325, pp.210-213, 2009.

P. V. Coelho and A. Brum-cde, Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Cad. Saude Publica, vol.25, pp.2229-2236, 2009.

L. Conboy, E. Varea, J. E. Castro, H. Sakouhi-ouertatani, T. Calandra et al., Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors, Mol. Psychiatry, vol.16, pp.533-547, 2011.

A. C. Conti, J. F. Cryan, A. Dalvi, I. Lucki, and J. A. Blendy, cAMP response element-binding protein is essential for the upregulation of brainderived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs, J. Neurosci, vol.22, pp.3262-3268, 2002.

I. A. Cook, A. M. Hunter, M. Abrams, B. Siegman, and A. F. Leuchter, Midline and right frontal brain function as a physiologic biomarker of remission in major depression, Psychiatry Res, vol.174, pp.152-157, 2009.

I. A. Cook, A. F. Leuchter, M. Morgan, E. Witte, W. F. Stubbeman et al., Early changes in prefrontal activity characterize clinical responders to antidepressants, Neuropsychopharmacology, vol.27, pp.294-298, 2002.

S. Couillard-despres, C. Wuertinger, M. Kandasamy, M. Caioni, K. Stadler et al., Ageing abolishes the effects of fluoxetine on neurogenesis, Mol. Psychiatry, vol.14, pp.856-864, 2009.

G. R. Cox, P. Callahan, R. Churchill, V. Hunot, S. N. Merry et al., Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents, Cochrane Database Syst. Rev, vol.11, p.8324, 2012.

J. F. Cryan, A. Dalvi, S. H. Jin, B. R. Hirsch, I. Lucki et al., Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs, J. Pharmacol. Exp. Ther, vol.298, pp.651-657, 2001.

J. F. Cryan and I. Lucki, Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine2C receptors, J. Pharmacol. Exp. Ther, vol.295, pp.1120-1126, 2000.

J. F. Cryan and I. Lucki, 5-HT4 receptors do not mediate the antidepressant-like behavioral effects of fluoxetine in a modified forced swim test, Eur. J. Pharmacol, vol.409, pp.295-299, 2000.

J. F. Cryan, O. F. O'leary, S. H. Jin, J. C. Friedland, M. Ouyang et al., Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotoninreuptake inhibitors, Proc. Natl. Acad. Sci. U.S.A, vol.101, pp.8186-8191, 2004.

B. Czéh, T. Welt, A. K. Fischer, A. Erhardt, W. Schmitt et al., Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis, Biol. Psychiatry, vol.52, pp.1457-1466, 2002.

D. J. David, K. C. Klemenhagen, K. A. Holick, M. D. Saxe, I. Mendez et al., Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3, 4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis, J. Pharmacol. Exp. Ther, vol.321, pp.237-248, 2007.

D. J. David, B. A. Samuels, Q. Rainer, J. Wang, D. Marsteller et al., Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression, Neuron, vol.62, pp.479-493, 2009.

R. J. Davidson, W. Irwin, M. J. Anderle, and N. H. Kalin, The neural substrates of affective processing in depressed patients treated with venlafaxine, Am. J. Psychiatry, vol.160, pp.64-75, 2003.

M. Dean, A. Rzhetsky, A. , and R. , The human ATP-binding cassette (ABC) transporter superfamily, Genome Res, vol.11, pp.1156-1166, 2001.

O. L. De-klerk, I. M. Nolte, P. M. Bet, F. J. Bosker, H. Snieder et al., ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder, Pharmacogenomics J, vol.13, pp.349-353, 2012.

P. L. Delgado, H. L. Miller, R. M. Salomon, J. Licinio, J. H. Krystal et al., Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action, Biol. Psychiatry, vol.46, pp.212-220, 1999.

K. Demyttenaere, P. Mesters, B. Boulanger, W. Dewe, M. H. Delsemme et al., Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine, J. Affect. Disord, vol.65, pp.243-252, 2001.

W. Deng, M. D. Saxe, I. S. Gallina, and F. H. Gage, Adult-born hippocampal dentate granule cells undergoing maturation modulate learning and memory in the brain, J. Neurosci, vol.29, pp.13532-13542, 2009.

S. L. Diaz, S. Doly, N. Narboux-nême, S. Fernández, P. Mazot et al., 5-HT(2B) receptors are required for serotonin-selective antidepressant actions, Mol. Psychiatry, vol.17, pp.154-163, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00652573

K. Domschke, U. Dannlowski, P. Ohrmann, B. Lawford, J. Bauer et al., Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression, Eur. Neuropsychopharmacol, vol.18, pp.751-759, 2008.

K. Domschke, C. Hohoff, L. S. Mortensen, T. Roehrs, J. Deckert et al., Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.32, pp.224-228, 2008.

C. H. Duman, L. Schlesinger, M. Kodama, D. S. Russell, and R. S. Duman, A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment, Biol. Psychiatry, vol.61, pp.661-670, 2007.

R. S. Duman, L. , and N. , A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists, Philos. Transl. R. Soc. Lond. B Biol. Sci, vol.367, pp.2475-2484, 2012.

W. C. Duncan, J. Selter, N. Brutsche, S. Sarasso, and C. A. Zarate, Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder, J. Affect. Disord, vol.145, pp.115-119, 2013.

J. J. Dunkin, A. F. Leuchter, I. A. Cook, J. E. Kasl-godley, M. Abrams et al., Executive dysfunction predicts nonresponse to fluoxetine in major depression, J. Affect. Disord, vol.60, pp.13-23, 2000.

D. Dupret, J. Revest, M. Koehl, F. Ichas, F. De-giorgi et al., Spatial relational memory requires hippocampal adult neurogenesis, PLoS ONE, vol.3, p.1959, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02325925

M. Egeland, J. Warner-schmidt, P. Greengard, and P. Svenningsson, Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum, Neuropharmacology, vol.61, pp.442-450, 2011.

A. J. Eisch and D. Petrik, Depression and hippocampal neurogenesis: a road to remission, Science, vol.338, pp.72-75, 2012.

R. Eitan, G. Landshut, T. Lifschytz, O. Einstein, T. Ben-hur et al., The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties, Int. J. Neuropsychopharmacol, vol.13, pp.553-561, 2010.

W. El-hage, J. F. Powell, and S. A. Surguladze, Vulnerability to depression: what is the role of stress genes in gene x environment interaction, Psychol. Med, vol.39, pp.1407-1411, 2009.

T. M. Eriksson, A. Alvarsson, T. L. Stan, X. Zhang, K. N. Hascup et al., Bidirectional regulation of emotional memory by 5-HT(1B) receptors involves hippocampal p11, Mol. Psychiatry, vol.18, pp.1096-1105, 2013.

H. A. Eyre, E. Papps, and B. T. Baune, Treating depression and depressionlike behavior with physical activity: an immune perspective, Front. Psychiatry, vol.4, p.3, 2013.

M. Fava, Diagnosis and definition of treatment-resistant depression, Biol. Psychiatry, vol.53, pp.649-659, 2003.

A. Fekadu, L. J. Rane, S. C. Wooderson, K. Markopoulou, L. Poon et al., Prediction of longer-term outcome of treatment-resistant depression in tertiary care, Br. J. Psychiatry, vol.201, pp.369-375, 2012.

A. Fekadu, S. C. Wooderson, K. Markopoulou, and A. J. Cleare, The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms, J. Clin. Psychiatry, vol.70, pp.952-957, 2009.

E. E. Feldmesser-reiss, The application of triiodothyronine in the treatment of mental disorders, J. Nerv. Ment. Dis, vol.127, pp.540-545, 1958.

F. F. Flach, C. I. Celian, and R. W. Rawson, Treatment of psychiatric disorders with triiodothyronine, Am. J. Psychiatry, vol.114, pp.841-842, 1958.

J. C. Fournier, R. J. Derubeis, S. D. Hollon, S. Dimidjian, J. D. Amsterdam et al., Antidepressant drug effects and depression severity: a patient-level meta-analysis, JAMA, vol.303, pp.47-53, 2010.

C. H. Fu, S. C. Williams, A. J. Cleare, J. Scott, M. T. Mitterschiffthaler et al., Neural responses to sad facial expressions in major depression following cognitive behavioral therapy, Biol. Psychiatry, vol.64, pp.505-512, 2008.

M. L. Furey, W. C. Drevets, E. M. Hoffman, E. Frankel, A. M. Speer et al., Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder, JAMA Psychiatry, vol.70, pp.280-290, 2013.

J. Fuss, N. M. Ben-abdallah, F. W. Hensley, K. Weber, R. Hellweg et al., Deletion of running-induced hippocampal neurogenesis by irradiation prevents development of an anxious phenotype in mice, PLoS ONE, vol.5, p.12769, 2010.

H. A. Garriock, M. Tanowitz, J. B. Kraft, V. C. Dang, E. J. Peters et al., Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder, Am. J. Psychiatry, vol.167, pp.565-573, 2010.

H. J. Gijsman, J. R. Geddes, J. M. Rendell, W. A. Nolen, and G. M. Goodwin, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials, Am. J. Psychiatry, vol.161, pp.1537-1547, 2004.

N. Goel, K. S. Plyler, D. Daniels, and T. L. Bale, Androgenic influence on serotonergic activation of the HPA stress axis, Endocrinology, vol.152, 2001.

K. Grasmäder, P. L. Verwohlt, M. Rietschel, A. Dragicevic, M. Müller et al., Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting, Eur. J. Clin. Pharmacol, vol.60, pp.329-336, 2004.

M. T. Grauer and M. Uhr, P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline, J. Psychopharmacol, vol.18, pp.66-74, 2004.

F. P. Guengerich, Cytochrome P450 and chemical toxicology, Chem. Res. Toxicol, vol.21, pp.70-83, 2008.

J. P. Guilloux, D. J. David, B. P. Guiard, F. Chenu, C. Repérant et al., Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice, Neuropsychopharmacology, vol.31, pp.2162-2172, 2006.

J. P. Guilloux, D. J. David, L. Xia, H. T. Nguyen, Q. Rainer et al., Characterization of 5-HT(1A/1B)-/-mice: an animal model sensitive to anxiolytic treatments, Neuropharmacology, vol.61, pp.478-488, 2011.

W. B. Guo, F. Liu, J. D. Chen, X. J. Xu, R. R. Wu et al., Altered white matter integrity of forebrain in treatmentresistant depression: a diffusion tensor imaging study with tract-based spatial statistics, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.38, pp.201-206, 2012.

M. Gupta, K. Holshausen, M. W. Best, R. Jokic, R. Milev et al., Relationships among neurocognition, symptoms, and functioning in treatment-resistant depression, Arch. Clin. Neuropsychol, vol.28, pp.272-281, 2013.

M. P. Hage and S. T. Azar, The link between thyroid function and depression, J. Thyroid Res, p.8, 2012.

A. Haj-mirzaian, N. Hamzeh, M. Javadi-paydar, M. R. Abdollahzadeh-estakhri, and A. R. Dehpour, Resistance to depression through interference of opioid and nitrergic systems in bile-duct ligated mice, Eur. J. Pharmacol, vol.708, pp.38-43, 2013.

C. Hamani, M. Diwan, C. E. Macedo, M. L. Brandão, J. Shumake et al., Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats, Biol. Psychiatry, vol.67, pp.117-124, 2010.

M. Hamilton, A rating scale for depression, J. Neurol. Neurosurg. Psychiatry, vol.23, pp.56-62, 1960.

N. D. Hanson, M. J. Owens, and C. B. Nemeroff, Depression, antidepressants, and neurogenesis: a critical reappraisal, Neuropsychopharmacology, vol.36, pp.2589-2602, 2011.

A. Heils, A. Teufel, S. Petri, G. Stöber, P. Riederer et al., Allelic variation of human serotonin transporter gene expression, J. Neurochem, vol.66, pp.2621-2624, 1996.

J. M. Hennings, T. Owashi, E. B. Binder, S. Horstmann, A. Menke et al., Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project, J. Psychiatr. Res, vol.43, pp.215-229, 2009.

C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update, Pharmacopsychiatry, vol.44, pp.195-235, 2011.

K. A. Holick, D. C. Lee, R. Hen, and S. C. Dulawa, Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor, Neuropsychopharmacology, vol.33, pp.406-417, 2008.

A. Holmes, R. J. Yang, D. L. Murphy, and J. N. Crawley, Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter, Neuropsychopharmacology, vol.27, pp.374-377, 2002.

F. Holsboer, The corticosteroid receptor hypothesis of depression, Neuropsychopharmacology, vol.23, pp.477-501, 2000.

J. Horacek, E. Rozehnalova, H. Rosslerova, and A. Dvorak, The influence of stressful life events on development of depression and treatment response in the population of patients in higher age, Ceska Slov. Psychiatr, vol.106, pp.311-317, 2011.

H. Hori, R. Yoshimura, N. Ueda, S. Eto, K. Shinkai et al., Grapefruit juice-fluvoxamine interaction -is it risky or not, J. Clin. Psychopharmacol, vol.23, pp.422-424, 2003.

S. Horstmann and E. B. Binder, Pharmacogenomics of antidepressant drugs, Pharmacol. Ther, vol.124, pp.57-73, 2009.

S. Horstmann, S. Lucae, A. Menke, J. M. Hennings, M. Ising et al., Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment, Neuropsychopharmacology, vol.35, pp.727-740, 2010.

S. Horstmann, S. Lucae, A. Menke, M. Ising, B. Muller-myhsok et al., Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients, Eur. Neuropsychopharm, vol.18, pp.214-215, 2008.

Y. Ibarguen-vargas, A. Surget, P. Vourc'h, S. Leman, C. R. Andres et al., Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress, Behav. Brain Res, vol.202, pp.245-251, 2009.

L. Ibrahim, N. Diazgranados, D. A. Luckenbaugh, R. Machado-vieira, J. Baumann et al., Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.35, pp.1155-1159, 2011.

N. Iovieno and G. I. Papakostas, Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis, J. Clin. Psychiatry, vol.73, pp.1300-1306, 2012.

M. Ising, S. Horstmann, S. Kloiber, S. Lucae, E. B. Binder et al., Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker, Biol. Psychiatry, vol.62, pp.47-54, 2007.

B. P. Jensen, R. L. Roberts, R. Vyas, G. Bonke, D. L. Jardine et al., Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers, Br. J. Clin. Pharmacol, vol.73, pp.619-628, 2012.

H. Jeon-slaughter, Economic factors in of patients' nonadherence to antidepressant treatment, Soc. Psychiatry Psychiatr. Epidemiol, vol.47, 1985.

W. Jiang, Y. Zhang, L. Xiao, J. Van-cleemput, S. Ji et al., Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects, J. Clin. Investig, vol.115, pp.3104-3116, 2005.

J. Jin, G. E. Sklar, V. Min-sen-oh, C. Li, and S. , Factors affecting therapeutic compliance: a review from the patient's perspective, Ther. Clin. Risk Manag, vol.4, pp.269-286, 2008.

L. Karlsson, B. Carlsson, C. Hiemke, J. Ahlner, F. Bengtsson et al., Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment, Eur. Neuropsychopharmacol, vol.23, pp.1636-1644, 2013.

M. Kato, T. Fukuda, A. Serretti, M. Wakeno, G. Okugawa et al., ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.32, pp.398-404, 2008.

M. Kato and A. Serretti, Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder, Mol. Psychiatry, vol.15, pp.473-500, 2010.

M. Kato, M. Wakeno, G. Okugawa, T. Fukuda, J. Azuma et al., No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression, Neuropsychobiology, vol.56, pp.167-171, 2007.

R. Keers and R. Uher, Gene-environment interaction in major depression and antidepressant treatment response, Curr. Psychiatry Rep, vol.14, pp.129-137, 2012.

R. Keers, R. Uher, B. Gupta, M. Rietschel, T. G. Schulze et al., Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP, J. Affect. Disord, vol.127, pp.337-342, 2010.

R. Keers, R. Uher, P. Huezo-diaz, R. Smith, S. Jaffee et al., Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project, Pharmacogenomics J, vol.11, pp.138-145, 2011.

R. C. Kessler, H. G. Birnbaum, V. Shahly, E. Bromet, I. Hwang et al., Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO world mental health survey initiative, Depress. Anxiety, vol.27, pp.351-364, 2010.

R. C. Kessler and T. B. Ustun, The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI), Int. J. Methods Psychiatr. Res, vol.13, pp.93-121, 2004.

N. A. Khin, Y. F. Chen, Y. Yang, P. Yang, and T. P. Laughren, Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications, J. Clin. Psychiatry, vol.72, pp.464-472, 2011.

J. J. Kim, L. Mandelli, C. U. Pae, D. De-ronchi, T. Y. Jun et al., Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.32, pp.375-379, 2008.

J. Kirchheiner, R. Lorch, E. Lebedeva, A. Seeringer, I. Roots et al., Genetic variants in FKBP5 affecting response to antidepressant drug treatment, Pharmacogenomics, vol.9, pp.841-846, 2008.

I. Kirsch, B. J. Deacon, T. B. Huedo-medina, A. Scoboria, T. J. Moore et al., Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration, PLoS Med, vol.5, 2008.

M. A. Kling, T. T. Geracioti, J. Licinio, D. Michelson, E. H. Oldfield et al., Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression, Psychopharmacol. Bull, vol.30, pp.489-494, 1994.

S. Kloiber, S. Ripke, M. A. Kohli, S. Reppermund, D. Salyakina et al., Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels, Eur. Neuropsychopharmacol, vol.23, pp.653-662, 2013.

V. J. Knott, J. I. Telner, Y. D. Lapierre, M. Browne, and E. R. Horn, , 1996.

, Quantitative EEG in the prediction of antidepressant response to imipramine, J. Affect. Disord, vol.39, pp.175-184

H. Kong, L. L. Sha, Y. Fan, M. Xiao, J. H. Ding et al., Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis, Neuropsychopharmacology, vol.34, pp.1263-1276, 2009.

V. Krishnan and E. J. Nestler, The molecular neurobiology of depression, Nature, vol.455, pp.894-902, 2008.

K. T. Kronmüller, J. Pantel, S. Köhler, D. Victor, F. Giesel et al., Hippocampal volume and 2-year outcome in depression, Br. J. Psychiatry, vol.192, pp.472-473, 2008.

D. J. Kupfer, E. Frank, and M. L. Phillips, Major depressive disorder: new clinical, neurobiological, and treatment perspectives, Lancet, vol.379, issue.11, pp.60602-60610, 2012.

B. Laika, S. Leucht, and W. Steimer, ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline, Clin. Chem, vol.52, pp.893-895, 2006.

R. W. Lam, Onset, time course and trajectories of improvement with antidepressants, Eur. Neuropsychopharmacol, vol.22, pp.492-498, 2012.

S. A. Langenecker, S. E. Kennedy, L. M. Guidotti, E. M. Briceno, L. S. Own et al., Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder, Biol. Psychiatry, vol.62, pp.1272-1280, 2007.

R. Lanzenberger, G. S. Kranz, D. Haeusler, E. Akimova, M. Savli et al., Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas, Neuroimage, vol.63, pp.874-881, 2012.

H. E. Lehmann, Therapy-resistant depressions -a clinical classification, Pharmakopsychiatr. Neuropsychopharmakol, vol.7, pp.156-163, 1974.

M. L. Lehmann, R. A. Brachman, K. Martinowich, R. J. Schloesser, and M. Herkenham, Glucocorticoids orchestrate divergent effects on mood through adult neurogenesis, J. Neuroscience, vol.33, pp.2961-2972, 2013.

M. Lekman, G. Laje, D. Charney, A. J. Rush, A. F. Wilson et al., The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort, Biol. Psychiatry, vol.63, pp.1103-1110, 2008.

A. F. Leuchter, I. A. Cook, W. S. Gilmer, L. B. Marangell, K. S. Burgoyne et al., Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder, Psychiatry Res, vol.169, pp.132-138, 2009.

A. F. Leuchter, I. A. Cook, S. P. Hamilton, K. L. Narr, A. Toga et al., Biomarkers to predict antidepressant response, Curr. Psychiatry Rep, vol.12, pp.553-562, 2010.

N. Li, B. Lee, R. J. Liu, M. Banasr, J. M. Dwyer et al., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, vol.329, pp.959-964, 2010.

T. Lifschytz, R. Segman, G. Shalom, B. Lerer, E. Gur et al., Basic mechanisms of augmentation of antidepressant effects with thyroid hormone, Curr. Drug Targets, vol.7, pp.203-210, 2006.

T. Lifschytz, P. Zozulinsky, R. Eitan, G. Landshut, S. Ohayon et al., Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT1A receptors: mediation by thyroid hormone ? receptors, J. Pharmacol. Exp. Ther, vol.337, pp.494-502, 2011.

K. M. Lin, Y. F. Chiu, I. J. Tsai, C. H. Chen, W. W. Shen et al., ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment, Pharmacogenet. Genomics, vol.21, pp.163-170, 2011.

G. X. Liu, G. Q. Cai, Y. Q. Cai, Z. J. Sheng, J. Jiang et al., Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1, Neuropsychopharmacology, vol.32, pp.1531-1539, 2007.

Z. Liu, F. Zhu, G. Wang, Z. Xiao, J. Tang et al., Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders, Neurosci. Lett, vol.414, pp.155-158, 2007.

A. M. Lozano, P. Giacobbe, C. Hamani, S. J. Rizvi, S. H. Kennedy et al., A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression, J. Neurosurg, vol.116, pp.315-322, 2012.

A. M. Lozano, H. S. Mayberg, P. Giacobbe, C. Hamani, R. C. Craddock et al., Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression, Biol. Psychiatry, vol.64, pp.461-467, 2008.

G. Lucas, V. V. Rymar, J. Du, O. Mnie-filali, C. Bisgaard et al., , 2007.

. Serotonin, )) receptor agonists are putative antidepressants with a rapid onset of action, Neuron, vol.55, issue.4, pp.712-725

G. M. Macqueen, K. Yucel, V. H. Taylor, K. Macdonald, and R. Joffe, Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder, Biol. Psychiatry, vol.64, pp.880-883, 2008.

T. M. Madsen, A. Treschow, J. Bengzon, T. G. Bolwig, O. Lindvall et al., Increased neurogenesis in a model of electroconvulsive therapy, Biol. Psychiatry, vol.47, pp.228-234, 2000.

J. E. Malberg, A. J. Eisch, E. J. Nestler, and R. S. Duman, Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus, J. Neurosci, vol.20, pp.9104-9110, 2000.

D. A. Malone, D. D. Dougherty, A. R. Rezai, L. L. Carpenter, and G. M. Friehs, Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression, Biol. Psychiatry, vol.65, pp.267-275, 2009.

L. Mandelli, E. Marino, A. Pirovano, R. Calati, R. Zanardi et al., Interaction between SERTPR and stressful life events on response to antidepressant treatment, Eur. Neuropsychopharmacol, vol.19, pp.64-67, 2009.

J. March, S. Silva, B. Vitiello, and . Team, The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks, J. Am. Acad. Child Adolesc. Psychiatry, vol.45, pp.1393-1403, 2006.

P. Martin, J. Massol, J. P. Belon, G. Gaudel, and P. Soubrié, Thyroid function and reversal by antidepressant drugs of depressive-like behavior (escape deficits) in rats, Neuropsychobiology, vol.18, pp.21-26, 1987.

A. Mateus-pinheiro, L. Pinto, J. M. Bessa, M. Morais, N. D. Alves et al., Sustained remission from depressive-like behavior depends on hippocampal neurogenesis, Transl. Psychiatry, vol.3, p.210, 2013.

H. S. Mayberg, S. K. Brannan, R. K. Mahurin, P. A. Jerabek, J. S. Brickman et al., Cingulate function in depression: a potential predictor of treatment response, Neuroreport, vol.8, pp.1057-1061, 1997.

H. S. Mayberg, A. M. Lozano, V. Voon, H. E. Mcneely, D. Seminowicz et al., Deep brain stimulation for treatment-resistant depression, Neuron, vol.45, pp.651-660, 2005.

M. L. Mayer, GRIK4 and the kainate receptor, Am. J. Psychiatry, vol.164, p.1148, 2007.

A. J. Mayorga, A. Dalvi, M. E. Page, S. Zimov-levinson, R. Hen et al., Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice, J. Pharmacol. Exp. Ther, vol.298, pp.1101-1107, 2001.

C. L. Mcgrath, M. E. Kelley, P. E. Holtzheimer, B. W. Dunlop, W. E. Craighead et al., Toward a neuroimaging treatment selection biomarker for major depressive disorder, JAMA Psychiatry, vol.12, pp.1-9, 2013.

P. Menu, F. Gressier, C. Verstuyft, P. Hardy, L. Becquemont et al., Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study, Neuropsychobiology, vol.62, pp.193-197, 2010.

A. Mihaljevic-peles, N. Bozina, M. Sagud, M. Rojnic-kuzman, and M. Lovric, MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.32, pp.1439-1444, 2008.

M. D. Miller, E. J. Lenze, M. A. Dew, E. Whyte, E. Weber et al., Effect of cerebrovascular risk factors on depression treatment outcome in later life, Am. J. Geriatr. Psychiatry, vol.10, pp.592-598, 2002.

M. Mitjans, C. Gastó, R. Catalán, L. Fañanás, and B. Arias, Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes, J. Psychopharmacol, vol.26, pp.1391-1398, 2012.

M. Mitjans, A. Serretti, C. Fabbri, C. Gastó, R. Catalán et al., Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment, Psychopharmacology (Berl.), vol.227, pp.509-519, 2013.

M. L. Molendijk, B. A. Bus, P. Spinhoven, B. W. Penninx, G. Kenis et al., Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment, Mol. Psychiatry, vol.16, pp.1088-1095, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00578453

S. M. Monroe, M. E. Thase, and A. D. Simons, Social factors and the psychobiology of depression: relations between life stress and rapid eye movement sleep latency, J. Abnorm. Psychol, vol.101, pp.528-537, 1992.

L. M. Monteggia, M. Barrot, C. M. Powell, O. Berton, V. Galanis et al., Essential role of brain-derived neurotrophic factor in adult hippocampal function, Proc. Natl. Acad. Sci. U.S.A, vol.101, pp.10827-10832, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00142913

S. A. Montgomery, A. , and M. , A new depression scale designed to be sensitive to change, Br. J. Psychiatry, vol.134, pp.382-389, 1979.

H. Y. Moon, S. H. Kim, Y. R. Yang, P. Song, H. S. Yu et al., Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise, Proc. Natl. Acad. Sci. U.S.A, vol.109, pp.13094-13099, 2012.

D. A. Mrazek, J. M. Biernacka, D. J. O'kane, J. L. Black, J. M. Cunningham et al., CYP2C19 variation and citalopram response, Pharmacogenet. Genomics, vol.21, pp.1-9, 2011.

C. Mulert, G. Juckel, M. Brunnmeier, S. Karch, G. Leicht et al., Prediction of treatment response in major depression: integration of concepts, J. Affect. Disord, vol.98, pp.215-225, 2007.

M. Mckinnon, K. Yucel, A. Nazarov, and G. Macqueen, A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder, J. Psychiatry Neurosci, vol.34, pp.41-54, 2009.

M. Nakamura, S. Ueno, A. Sano, and H. Tanabe, The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants, Mol. Psychiatry, vol.5, pp.32-38, 2000.

T. Nakashiba, J. D. Cushman, K. A. Pelkey, S. Renaudineau, D. L. Buhl et al., Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion, Cell, vol.149, pp.188-201, 2012.

S. Narasimhan and F. W. Lohoff, Pharmacogenetics of antidepressant drugs: current clinical practice and future directions, Pharmacogenomics, vol.13, pp.441-464, 2012.

J. C. Nelson, C. M. Clary, A. C. Leon, and L. S. Schneider, Symptoms of late-life depression: frequency and change during treatment, Am. J. Geriatr. Psychiatry, vol.13, pp.520-526, 2005.

. Nice, Depression: Management of Depression in Primary and Secondary Care. London: Clinical guidelines, CG23, National Institute for Clinical Excellence, 2004.

A. A. Nierenberg and L. M. Dececco, Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression, J. Clin. Psychiatry, vol.62, pp.5-9, 2001.

A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. R. Thase et al., A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1519-1530, 2006.

M. Nollet, P. Gaillard, A. Tanti, V. Girault, C. Belzung et al., Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression, Neuropsychopharmacology, vol.37, pp.2210-2221, 2012.

F. E. O'brien, T. G. Dinan, B. T. Griffin, and J. F. Cryan, Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings, Br. J. Pharmacol, vol.165, pp.289-312, 2012.

Y. S. Oh, P. Gao, K. W. Lee, I. Ceglia, J. S. Seo et al., SMARCA3, a chromatin remodeling factor, is required for p11-dependent antidepressant action, Cell, vol.152, pp.831-843, 2013.

O. F. O'leary, A. J. Bechtholt, J. J. Crowley, T. E. Hill, M. E. Page et al., Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test, Psychopharmacology (Berl.), vol.192, pp.357-371, 2007.

C. U. Pae, L. Mandelli, A. Serretti, A. A. Patkar, J. J. Kim et al., Heat-shock protein-70 genes and response to antidepressants in major depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.31, pp.1006-1011, 2007.

C. U. Pae, A. Serretti, L. Mandelli, D. De-ronchi, A. A. Patkar et al., Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy, Pharmacogenet. Genomics, vol.17, pp.69-75, 2007.

G. I. Papakostas, R. Cooper-kazaz, B. C. Appelhof, M. A. Posternak, D. P. Johnson et al., Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies, Int. Clin. Psychopharmacol, vol.24, pp.19-25, 2009.

S. Papiol, B. Arias, C. Gastó, B. Gutiérrez, R. Catalán et al., Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment, J. Affect. Disord, vol.104, pp.83-90, 2007.

C. M. Pariante, Depression, stress and the adrenal axis, J. Neuroendocrinol, vol.15, pp.811-812, 2003.

C. M. Pariante and A. H. Miller, Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment, Biol. Psychiatry, vol.49, pp.391-404, 2001.

G. Paslakis, I. Heuser, U. Schweiger, and M. Deuschle, A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine, J. Psychiatr. Res, vol.44, pp.1154-1157, 2010.

A. M. Pereira, J. Tiemensma, and J. A. Romijn, Neuropsychiatric disorders in cushing's syndrome, Neuroendocrinology, vol.92, pp.65-70, 2010.

T. D. Perera, J. D. Coplan, S. H. Lisanby, C. M. Lipira, M. Arif et al., Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates, J. Neurosci, vol.27, pp.4894-4901, 2007.

T. D. Perera, A. J. Dwork, K. A. Keegan, L. Thirumangalakudi, C. M. Lipira et al., Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates, PLoS ONE, vol.6, p.17600, 2011.

E. J. Peters, S. L. Slager, J. B. Kraft, G. D. Jenkins, M. S. Reinalda et al., Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample, PLoS ONE, vol.3, p.1872, 2008.

D. Petrik, D. C. Lagace, and A. J. Eisch, The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building, Neuropharmacology, vol.62, pp.21-34, 2012.

M. Pilhatsch, C. Winter, K. Nordström, B. Vennström, M. Bauer et al., Increased depressive behaviour in mice harboring the mutant thyroid hormone receptor alpha 1, Behav. Brain Res, vol.214, pp.187-192, 2010.

D. A. Pizzagalli, Frontocingulate dysfunction in depression: toward biomarkers of treatment response, Neuropsychopharmacology, vol.36, pp.183-206, 2011.

D. Pizzagalli, R. D. Pascual-marqui, J. B. Nitschke, T. R. Oakes, C. L. Larson et al., Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis, Am. J. Psychiatry, vol.158, pp.405-415, 2001.

S. Porcelli, C. Fabbri, A. Drago, S. Gibiino, D. De-ronchi et al., Genetics and antidepressants: where we are, Clin Neuropsychiatry, vol.8, pp.99-150, 2011.

A. Price, L. Rayner, E. Okon-rocha, A. Evans, K. Valsraj et al., Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials, J. Neurol. Neurosurg. Psychiatry, vol.82, pp.914-923, 2011.

R. Ramasubbu, S. Beaulieu, V. H. Taylor, A. Schaffer, and R. S. Mcintyre, The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles, Ann. Clin. Psychiatry, vol.24, pp.82-90, 2012.

A. Reif, S. Fritzen, M. Finger, A. Strobel, M. Lauer et al., Neural stem cell proliferation is decreased in schizophrenia, but not in depression, Mol. Psychiatry, vol.11, pp.514-522, 2006.

J. M. Revest, D. Dupret, M. Koehl, C. Funk-reiter, N. Grosjean et al., Adult hippocampal neurogenesis is involved in anxiety-related behaviors, Mol. Psychiatry, vol.14, pp.959-967, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02325920

D. Revesz, M. Tjernstrom, E. Ben-menachem, and T. Thorlin, Effects of vagus nerve stimulation on rat hippocampal progenitor proliferation, Exp. Neurol, vol.214, pp.259-265, 2008.

J. W. Richardson-jones, C. P. Craige, B. P. Guiard, A. Stephen, K. L. Metzger et al., 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants, Neuron, vol.65, pp.40-52, 2010.

E. Richelson, Pharmacokinetic interactions of antidepressants, J. Clin. Psychiatry, vol.59, pp.22-26, 1998.

A. Rivero-santana, L. Perestelo-perez, J. Pérez-ramos, P. Serrano-aguilar, . De-las et al., Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies, Patient Prefer. Adherence, vol.7, pp.151-169, 2013.

R. L. Roberts, P. R. Joyce, R. T. Mulder, E. J. Begg, and M. A. Kennedy, A common P-glycoprotein polymorphism is associated with nortriptylineinduced postural hypotension in patients treated for major depression, Pharmacogenomics J, vol.2, pp.191-196, 2002.

J. P. Roiser, R. Elliott, and B. J. Sahakian, Cognitive mechanisms of treatment in depression, Neuropsychopharmacology, vol.37, pp.117-136, 2012.

H. G. Ruhé, G. Van-rooijen, J. Spijker, F. P. Peeters, and A. H. Schene, Staging methods for treatment resistant depression. A systematic review, J. Affect. Disord, vol.137, pp.35-45, 2012.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1905-1917, 2006.

T. Saarelainen, P. Hendolin, G. Lucas, E. Koponen, M. Sairanen et al., Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects, J. Neurosci, vol.23, pp.349-357, 2003.

H. A. Sackeim, J. Prudic, D. P. Devanand, P. Decina, B. Kerr et al., The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression, J. Clin. Psychopharmacol, vol.10, pp.96-104, 1990.

A. Sahay, K. N. Scobie, A. S. Hill, C. M. O'carroll, M. A. Kheirbek et al., Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation, Nature, vol.472, pp.466-470, 2011.

G. Salvadore, B. R. Cornwell, V. Colon-rosario, R. Coppola, C. Grillon et al., Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine, Biol. Psychiatry, vol.65, pp.289-295, 2009.

G. Sanacora, S. F. Kendell, Y. Levin, A. A. Simen, L. R. Fenton et al., Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms, Biol. Psychiatry, vol.61, pp.822-825, 2007.

G. Sanacora, C. A. Zarate, J. H. Krystal, and H. K. Manji, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders, Nat. Rev. Drug. Discov, vol.7, pp.426-437, 2008.

L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia et al., Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants, Science, vol.301, pp.805-809, 2003.

J. E. Sarginson, L. C. Lazzeroni, H. S. Ryan, B. D. Ershoff, A. F. Schatzberg et al., ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression, Pharmacogenet. Genomics, vol.20, pp.467-475, 2010.

N. Sartorius, Description and classification of depressive disorders. Contributions for the definition of the therapy-resistance and of therapy resistant depressions, Pharmakopsychiatr. Neuropsychopharmakol, vol.7, pp.76-79, 1974.

S. Saxena, A. L. Brody, M. L. Ho, N. Zohrabi, K. M. Maidment et al., Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression, Am. J. Psychiatry, vol.160, pp.522-532, 2003.

J. F. Scherrer, T. Chrusciel, L. D. Garfield, K. E. Freedland, R. M. Carney et al., Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction, Br. J. Psychiatry, vol.200, pp.137-142, 2012.

A. H. Schinkel, E. Wagenaar, L. Van-deemter, C. A. Mol, and P. Borst, Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J. Clin. Invest, vol.96, pp.1698-1705, 1995.

R. J. Schloesser, M. Lehmann, K. Martinowich, H. K. Manji, and M. Herkenham, Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress, Mol. Psychiatry, vol.15, pp.1152-1163, 2010.

R. J. Schloesser, H. K. Manji, and K. Martinowich, Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response, Neuroreport, vol.20, pp.553-557, 2009.

E. F. Schmidt, J. L. Warner-schmidt, B. G. Otopalik, S. B. Pickett, P. Greengard et al., Identification of the cortical neurons that mediate antidepressant responses, Cell, vol.149, pp.1152-1163, 2012.

M. V. Schmidt, M. Paez-pereda, F. Holsboer, and F. Hausch, The prospect of FKBP51 as a drug target, Chem. Med. Chem, vol.7, pp.1351-1359, 2012.

C. Schmuckermair, S. Gaburro, A. Sah, R. Landgraf, S. B. Sartori et al., Behavioral and neurobiological effects of deep brain stimulation in a mouse model of high anxiety-and depression-like behavior, Neuropsychopharmacology, vol.38, pp.1234-1244, 2013.

C. Schüle, T. C. Baghai, D. Eser, S. Häfner, C. Born et al., The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression, PLoS ONE, vol.4, p.4324, 2009.

R. Schulz, R. A. Drayer, and B. L. Rollman, Depression as a risk factor for non-suicide mortality in the elderly, Biol. Psychiatry, vol.52, pp.205-225, 2002.

M. Serra-blasco, M. J. Portella, B. Gómez-ansón, J. De-diego-adeliño, Y. Vives-gilabert et al., Effects of illness duration and treatment resistance on grey matter abnormalities in major depression, Br. J. Psychiatry, vol.202, pp.434-440, 2013.

A. Serretti, R. Zanardi, D. Rossini, C. Cusin, R. Lilli et al., Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity, Mol. Psychiatry, vol.6, pp.586-592, 2001.

D. V. Sheehan, M. S. Keene, M. Eaddy, S. Krulewicz, J. E. Kraus et al., Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders, CNS Drugs, vol.22, pp.963-973, 2008.

R. C. Shelton, O. Osuntokun, A. N. Heinloth, and S. A. Corya, Therapeutic options for treatment-resistant depression, CNS Drugs, vol.24, pp.131-161, 2010.

P. R. Shiroma, Y. E. Geda, and D. A. Mrazek, Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry, Pharmacogenomics, vol.11, pp.1305-1330, 2010.

T. J. Shors, G. Miesegaes, A. Beylin, M. Zhao, T. Rydel et al., Neurogenesis in the adult is involved in the formation of trace memories, Nature, vol.410, pp.372-376, 2001.

A. B. Singh, C. A. Bousman, C. H. Ng, K. Byron, B. et al., ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression, Transl. Psychiatry, vol.2, p.198, 2012.

E. Smeraldi, A. Serretti, P. Artioli, C. Lorenzi, and M. Catalano, Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants, Psychiatr. Genet, vol.16, pp.153-158, 2006.

J. S. Snyder, A. Soumier, M. Brewer, J. Pickel, C. et al., Adult hippocampal neurogenesis buffers stress responses and depressive behaviour, Nature, vol.476, pp.458-461, 2011.

N. Sonino, M. Boscaro, G. Ambroso, G. Merola, and F. Mantero, Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide, IRCS Med. Sci, vol.14, pp.485-486, 1986.

N. Sonino and G. A. Fava, Residual symptoms in depression. An emerging therapeutic concept, Prog. NeuroPsychopharmacol. Biol. Psychiatry, vol.26, pp.763-770, 2002.

N. Sonino, G. A. Fava, P. Belluardo, M. E. Girelli, and M. Boscaro, Course of depression in Cushing's syndrome: response to treatment and comparison with Graves' disease, Horm. Res, vol.39, pp.202-206, 1993.

D. Souery, J. Amsterdam, C. De-montigny, Y. Lecrubier, S. Montgomery et al., Treatment resistant depression: methodological overview and operational criteria, Eur. Neuropsychopharmacol, vol.9, issue.98, pp.4-6, 1999.

D. Souery, P. Oswald, I. Massat, U. Bailer, J. Bollen et al., Group for the study of resistant depression. clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study, J. Clin. Psychiatry, vol.68, pp.1062-1070, 2007.

P. Stawski, H. Janovjak, and D. Trauner, Pharmacology of ionotropic glutamate receptors: a structural perspective, Bioorg. Med. Chem, vol.18, pp.7759-7772, 2010.

M. A. Steiner, K. Wanisch, K. Monory, G. Marsicano, E. Borroni et al., Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice, Pharmacogenomics J, vol.8, pp.196-208, 2008.

J. Stemmelin, C. Cohen, I. Yalcin, P. Keane, and G. Griebel, Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress, Behav. Brain Res, vol.206, pp.310-312, 2010.

A. Surget, M. Saxe, S. Leman, Y. Ibarguen-vargas, S. Chalon et al., Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal, Biol. Psychiatry, vol.64, pp.293-301, 2008.

A. Surget, A. Tanti, E. D. Leonardo, A. Laugeray, Q. Rainer et al., Antidepressants recruit new neurons to improve stress response regulation, Mol. Psychiatry, vol.16, pp.1177-1188, 2011.

Y. Suzuki, T. Sugai, N. Fukui, J. Watanabe, S. Ono et al., CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics, J. Psychopharmacol, vol.25, pp.908-914, 2011.

P. Svenningsson, K. Chergui, I. Rachleff, M. Flajolet, X. Zhang et al., Alterations in 5-HT1B receptor function by p11 in depression-like states, Science, vol.311, pp.77-80, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02185479

W. Swardfager, N. Herrmann, R. S. Mcintyre, G. Mazereeuw, K. Goldberger et al., Potential roles of zinc in the pathophysiology and treatment of major depressive disorder, Neurosci. Biobehav. Rev, vol.37, pp.911-929, 2013.

A. Tadi?, M. J. Müller, D. Rujescu, R. Kohnen, H. H. Stassen et al., The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression, Am. J. Med. Genet. B. Neuropsychiatr. Genet, vol.144, pp.325-331, 2007.

A. Tanti and C. Belzung, Hippocampal neurogenesis: a biomarker for depression or antidepressant effects. Methodological considerations and perspectives for future research, Cell Tissue Res, vol.354, pp.203-219, 2013.

A. Tanti and C. Belzung, Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants regionspecific, Neuroscience, vol.252, pp.234-252, 2013.

R. Tao, G. Emslie, T. Mayes, P. Nakonezny, B. Kennard et al., Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder, J. Am. Acad. Child Adolesc. Psychiatry, vol.48, pp.71-78, 2009.

, Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test, Eur. J. Pharmacol, vol.487, pp.133-142

B. P. Taylor, G. E. Bruder, J. W. Stewart, P. J. Mcgrath, J. Halperin et al., Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients, Am. J. Pyschiatry, vol.163, pp.73-78, 2006.

E. Tedeschini, Y. Levkovitz, N. Iovieno, V. E. Ameral, J. C. Nelson et al., Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials, J. Clin. Psychiatry, vol.72, pp.1660-1668, 2011.

M. E. Thase and A. J. Rush, When at first you don't succeed: sequential strategies for antidepressant nonresponders, J. Clin. Psychiatry, vol.58, pp.23-29, 1997.

L. Tondo, R. J. Baldessarini, G. Vázquez, B. Lepri, and C. Visioli, Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders, Acta Psychiatr. Scand, vol.127, pp.355-364, 2013.

A. C. Trillat, I. Malagié, M. Bourin, C. Jacquot, R. Hen et al., Homozygote mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors, C. R. Seances Soc. Biol. Fil, vol.192, pp.1139-1147, 1998.

M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am. J. Psychiatry, vol.163, pp.28-40, 2006.

S. Tronel, L. Belnoue, N. Grosjean, J. M. Revest, P. V. Piazza et al., Adult-born neurons are necessary for extended contextual discrimination, Hippocampus, vol.22, pp.292-298, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02326414

S. Trouche, B. Bontempi, P. Roullet, R. , and C. , Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory, Proc. Natl. Acad. Sci. U.S.A, vol.106, pp.5919-5924, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00365297

S. J. Tsai, Y. T. Gau, C. J. Hong, Y. J. Liou, Y. W. Yu et al., Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients, J. Affect. Disord, vol.113, pp.183-187, 2009.

S. J. Tsai, C. J. Hong, T. J. Chen, Y. , and Y. W. , Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment, Am. J. Med. Genet. B. Neuropsychiatr. Genet, vol.144, pp.1097-1098, 2007.

K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki et al., Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone, J. Biol. Chem, vol.267, pp.24248-24252, 1992.

N. Ueda, R. Yoshimura, W. Umene-nakano, A. Ikenouchi-sugita, H. Hori et al., Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers, World J. Biol. Psychiatry, vol.10, issue.4, pp.832-835, 2009.

M. Uhr and M. T. Grauer, abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice, J. Psychiatr. Res, vol.37, pp.179-185, 2003.

M. Uhr, M. T. Grauer, and F. Holsboer, Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) Pglycoprotein gene disruption, Biol. Psychiatry, vol.54, issue.03, p.74, 2003.

M. Uhr, F. Holsboer, and M. B. Müller, Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins, 2002.

, J. Neuroendocrinol, vol.14, pp.753-759

M. Uhr, T. Steckler, A. Yassouridis, and F. Holsboer, Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption, Neuropsychopharmacology, vol.22, pp.380-387, 2000.

M. Uhr, A. Tontsch, C. Namendorf, S. Ripke, S. Lucae et al., Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression, Neuron, vol.57, pp.203-209, 2008.

G. Ulrich, E. Renfordt, and K. Frick, The topographical distribution of alpha-activity in the resting EEG of endogenous-depressive inpatients with and without clinical-response to pharmacotherapy, Pharmacopsychiatry, vol.19, pp.272-273, 1986.

, Frontiers in Pharmacology | Neuropharmacology, vol.4, 2013.

E. Tatarczyñska, A. K?odzi?ska, K. Stachowicz, and E. Chojnacka-wójcik, , 2004.

E. F. Van-rossum, E. B. Binder, M. Majer, J. W. Koper, M. Ising et al., Polymorphisms of the glucocorticoid receptor gene and major depression, Biol. Psychiatry, vol.59, pp.681-688, 2006.

G. H. Vázquez, L. Tondo, J. Undurraga, and R. J. Baldessarini, Overview of antidepressant treatment of bipolar depression, Int. J. Neuropsychopharmacol, vol.22, pp.1-13, 2013.

A. C. Vergouwen, A. Bakker, W. J. Katon, T. J. Verheij, and F. Koerselman, Improving adherence to antidepressants: a systematic review of interventions, J. Clin. Psychiatry, vol.64, pp.1415-1420, 2003.

M. Vermeiden, W. W. Van-den-broek, P. G. Mulder, and T. K. Birkenhäger, Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients, J. Psychopharmacol, vol.24, pp.497-502, 2010.

V. Vialou, A. J. Robison, Q. C. Laplant, H. E. Covington, and D. M. Dietz, DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses, Nat. Neurosci, vol.13, pp.745-752, 2010.

J. S. Wang, H. J. Zhu, B. B. Gibson, J. S. Markowitz, J. L. Donovan et al., Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein, Biol. Pharm. Bull, vol.31, pp.231-234, 2008.

J. W. Wang, D. J. David, J. E. Monckton, F. Battaglia, and R. Hen, Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells, J. Neuroscience, vol.28, pp.1374-1384, 2008.

J. L. Warner-schmidt, E. Y. Chen, X. Zhang, J. J. Marshall, A. Morozov et al., A role for p11 in the antidepressant action of brainderived neurotrophic factor, Biol. Psychiatry, vol.68, pp.528-535, 2010.

J. L. Warner-schmidt, M. Flajolet, A. Maller, E. Y. Chen, H. Qi et al., Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation, J. Neurosci, vol.29, pp.1937-1946, 2009.

J. L. Warner-schmidt, K. E. Vanover, E. Y. Chen, J. J. Marshall, and P. Greengard, Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans, Proc. Natl. Acad. Sci. U.S.A, vol.108, pp.9262-9267, 2011.

J. Weiss, S. M. Dormann, M. Martin-facklam, C. J. Kerpen, N. Ketabi-kiyanvash et al., Inhibition of P-glycoprotein by newer antidepressants, J. Pharmacol. Exp. Ther, vol.305, pp.197-204, 2003.

G. R. Williams, Neurodevelopmental and neurophysiological actions of thyroid hormone, J. Neuroendocrinol, vol.20, pp.784-794, 2008.

I. C. Wilson, A. J. Prange, and P. P. Lara, Triiodothyronine alone and with imipramine in the treatment of depressed women, The Thyroid Axis, Drugs and Behavior, pp.49-61, 1974.

J. Winner, J. D. Allen, C. A. Altar, and A. Spahic-mihajlovic, Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression, Transl. Psychiatry, vol.3, p.242, 2013.

J. Wu, M. S. Buchsbaum, J. C. Gillin, C. Tang, S. Cadwell et al., Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex, Am. J. Psychiatry, vol.156, pp.1149-1158, 1999.

Z. Xu, Z. Zhang, Y. Shi, M. Pu, Y. Yuan et al., Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response, J. Affect. Disord, vol.133, pp.165-173, 2011.

I. Yalcin, F. Aksu, and C. Belzung, Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol, Eur. J. Pharmacol, vol.514, pp.165-174, 2005.

O. Q. Yin, Y. K. Wing, Y. Cheung, Z. J. Wang, S. L. Lam et al., Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients, J. Clin. Psychopharmacol, vol.26, pp.367-372, 2006.

E. A. Young, R. F. Haskett, V. Murphy-weinberg, S. J. Watson, A. et al., Loss of glucocorticoid fast feedback in depression, Arch. Gen. Psychiatry, vol.48, pp.693-699, 1991.

H. Yu, D. D. Wang, Y. Wang, T. Liu, F. S. Lee et al., Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants, J. Neurosci, vol.32, pp.4092-4101, 2012.

Y. W. Yu, S. J. Tsai, C. J. Hong, T. J. Chen, M. C. Chen et al., Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response, Neuropsychopharmacology, vol.30, pp.1719-1723, 2005.

H. T. Zhang, L. R. Whisler, Y. Huang, Y. Xiang, and J. M. Donnell, Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior, Neuropsychopharmacology, vol.34, pp.1067-1077, 2009.

L. Zhang, H. Li, T. P. Su, J. L. Barker, D. Maric et al., p11 is up-regulated in the forebrain of stressed rats by glucocorticoid acting via two specific glucocorticoid response elements in the p11 promoter, Neuroscience, vol.153, pp.1126-1134, 2008.

A. Zobel, A. Joe, N. Freymann, H. Clusmann, J. Schramm et al., Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach, Psychiatry Res, vol.139, pp.165-179, 2005.

, Conflict of Interest Statement: The authors declare that the research was con